参考文献/References:
[1] Chen WY, Wight DC, Wagner TE, et al. Expression of a
mutated bovine growth hormone gene suppresses growth of
transgenic mice [J]. Proc Natl Acad Sci USA, 1990, 87:
5061-5065.
[2] Fuh G, Cunningham BC, Fukunaga R, et al. Rational design
of potent antagonists to the human growth hormone receptor
[J]. Science, 1992, 256: 1677-1680.
[3] Trainer PJ, Drake WM, Katznelson L, et al. Treatment of
acromegaly with the growth hormone-receptor antagonist
pegvisomant [J]. N Engl J Med, 2000, 342(16): 1171-1177.
[4] Sesmilo G, Fairfield WP, Katznelson L, et al. Cardiovascular
risk factors in acromegaly before and after normalization of
serum IGF-I levels with the GH antagonist pegvisomant [J].
J Clin Endocrinol Metab, 2002, 87(4): 1692-1699.
[5] Fairfield WP, Sesmilo G, Katznelson L, et al. Effects of a
growth hormone receptor antagonist on bone markers in
acromegaly [J]. Clin Endocrinol, 2002, 57(3): 387-390.
[6] Ghigo E, Biller BM, Colao A, et al. Comparison of pegviso-
mant and long-acting octreotide in patients with acromegaly
naive to radiation and medical therapy [J]. J Endocrinol
Invest, 2009, 32(11): 924-933.
[7] Madsen M, Poulsen PL, Orskov H, et al. Cotreatment with
pegvisomant and a Somatostatin Analog (SA) in SA-respon-
sive acromegalic patients [J]. J Clin Endocrinol Metab,
2011, 96(8): 2405-2413.
[8] VanderLely AJ, Hutson RK, Trainer PJ, et al. Long-term
treatment of acromegaly with pegvisomant, agrowth hormone
receptor antagonist [J]. Lancet, 2001, 358: 1754-1759.
[9] Colao A, Pivonello R, Auriemma RS, et al. Efficacy of 12-
month treatment with the GH receptor antagonistpegviso-
mant in patients with acromegaly resistant to long-term,
high-dose somatostatin analog treatment: effect on IGF-I
levels, tumor mass, hypertension and glucose tolerance [J].
Eur J endocrinol, 2006, 154: 467-477.
[10] Veldhuis JD, Bidlingmaier M, Anderson SM, et al. Impact of
experimental blockade of peripheral growth hormone(GH)
receptors on the kinetics of endogenous and exogenous GH
removal in healthy women and men [J]. J Clin Endocrinol
Metab, 2002, 87(12): 5737-5745.
[11] Parkinson C, Trainer PJ. The place of pegvisomant in the
management of acromegaly [J]. Expert Opin Investig Drugs,
2001, 10(9): 1725-1735.
[12] Pivonello R, Galderisi M, Auriemma RS, et al. Treatment
with growth hormone receptor antagonist in acromegaly:
effect on cardiac structure and performance [J]. J Clin
Endocrinol Metab, 2007, 92: 476-482.
[13] Parkinson C, Kassem M, Heickendorff L, et al. Pegviso-
mant-induced serum insulin-like growth factor-Ⅰnormali-
zation in patients with acromegaly returns elevated markers
of bone turnover to normal [J]. J Clin Endocrinol Metab,
2003, 88: 5650-5655.
相似文献/References:
[1]傅 炜 卞留贯 陈 晓 钟志宏 孙昱皓 孙青芳.垂体生长激素腺瘤经蝶手术预后的影响因素分析[J].中国临床神经外科杂志,2015,(10):584.[doi:10.13798/j.issn.1009-153X.2015.10.003]
FU Wei,BIAN Liu-guan,CHEN Xiao,et al.Analysis of factors related to prognoses in patients with growth hormone-secreting pituitary adenomas after transsphenoidal surgery[J].,2015,(10):584.[doi:10.13798/j.issn.1009-153X.2015.10.003]
[2]陈 曦 陈 娟 谢蕊繁 徐 钰 胡 航 李 然 叶 飞 雷 霆.人脑垂体生长激素腺瘤PKCδ、ERK1/2、gsp癌基因的表达关联性分析[J].中国临床神经外科杂志,2015,(04):225.[doi:10.13798/j.issn.1009-153X.2015.04.011]
CHEN Xi,CHEN Juan,XIE Rui-fan,et al.Expressions gsp oncogene, PKCδ and ERK1/2 in human somatotrophinomas and relationship among them[J].,2015,(10):225.[doi:10.13798/j.issn.1009-153X.2015.04.011]
[3]林伟标 林少华.神经内镜与显微镜下经鼻蝶入路手术治疗垂体生长激素腺瘤[J].中国临床神经外科杂志,2018,(08):554.[doi:doi:10.13798/j.issn.1009-153X.2018.08.015]
[4]郭晓鹏 赵羽西 高 路 姚 勇 邓 侃 连 伟 王任直 幸 兵.经蝶手术治疗垂体生长激素腺瘤合并空蝶鞍综合征疗效分析[J].中国临床神经外科杂志,2015,(05):265.[doi:10.13798/j.issn.1009-153X.2015.05.003]
GUO Xiao-peng,ZHAO Yu-xi,GAO Lu,et al.Therapeutic effects of transsphenoidal microsurgery on growth-hormone-secreting pituitary adenomas associated with empty sella syndrome (report of 41 cases)[J].,2015,(10):265.[doi:10.13798/j.issn.1009-153X.2015.05.003]